Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Reta GLP3 is an investigational once-weekly medication being studied for its potential role in weight management and metabolic health. It is designed to activate three hormone receptors—GIP, GLP-1, and glucagon—which may influence appetite, energy balance, glucose regulation, and body weight.
Unlike medications that target one or two hormone pathways, retatrutide is being studied as a triple receptor agonist:
GIP – involved in glucose regulation and metabolic signaling
GLP-1 – associated with appetite regulation, satiety, and blood sugar control
Glucagon – involved in energy expenditure and metabolism
Researchers are studying whether the combination of these pathways can provide meaningful improvements in body weight and other metabolic outcomes.
Reta GLP3 is an investigational once-weekly medication being studied for its potential role in weight management and metabolic health. It is designed to activate three hormone receptors—GIP, GLP-1, and glucagon—which may influence appetite, energy balance, glucose regulation, and body weight.
Unlike medications that target one or two hormone pathways, retatrutide is being studied as a triple receptor agonist:
GIP – involved in glucose regulation and metabolic signaling
GLP-1 – associated with appetite regulation, satiety, and blood sugar control
Glucagon – involved in energy expenditure and metabolism
Researchers are studying whether the combination of these pathways can provide meaningful improvements in body weight and other metabolic outcomes.